• ImmunoBiochem and Orb Therapeutics became the first Canadian recipients of Mission BioCapital’s Platinum Tickets, selected from fewer than 2% of applicants.
• The program offers up to $500,000 in pre-seed capital; ImmunoBiochem will receive seed funding, laboratory space and drug-discovery support.
• A $3.5 million federal investment provided a significant portion of ImmunoBiochem’s seed funding to support scale-up and pipeline development.
• ImmunoBiochem’s lead candidate, IMB-216P, targets inflammatory bowel disease by selectively degrading inflammatory proteins in pathogenic T cells while sparing regulatory T cells.
• ImmunoBiochem reported durable disease control following a single intravenous or subcutaneous dose in humanized chronic-colitis models.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Toronto Innovation Acceleration Partners published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.